Activation and expansion of T-cells using an engineered...

Details Activation and expansion of T-cells using an engineered... Activation and expansion of T-cells using an engineered...

2003-06-13

2009-12-29

Haddad, Maher M (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S326000, C435S440000, C435S455000

Reexamination Certificate

active

07638326

ABSTRACT:
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.

REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
patent: 5190878 (1993-03-01), Wilhelm
patent: 5529921 (1996-06-01), Peterson et al.
patent: 5827642 (1998-10-01), Riddell et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5888807 (1999-03-01), Palsson et al.
patent: 5962320 (1999-10-01), Robinson
patent: 5985653 (1999-11-01), Armstrong et al.
patent: 6001365 (1999-12-01), Peterson et al.
patent: 6096532 (2000-08-01), Armstrong et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6355479 (2002-03-01), Webb et al.
patent: 6464973 (2002-10-01), Levitsky et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6867041 (2005-03-01), Berenson et al.
patent: 6887466 (2005-05-01), June et al.
patent: 6890753 (2005-05-01), Flyer et al.
patent: 6905681 (2005-06-01), June et al.
patent: 6905874 (2005-06-01), Berenson et al.
patent: 7175843 (2007-02-01), June et al.
patent: 2002/0058019 (2002-05-01), Berenson et al.
patent: 2002/0119568 (2002-08-01), Berenson et al.
patent: 2003/0147869 (2003-08-01), Riley et al.
patent: 2003/0224520 (2003-12-01), June et al.
patent: 2004/0101519 (2004-05-01), June et al.
patent: 2004/0191235 (2004-09-01), Groux et al.
patent: 2004/0241162 (2004-12-01), Berenson et al.
patent: 2005/0003484 (2005-01-01), Hirano et al.
patent: 2006/0034810 (2006-02-01), Riley et al.
patent: 2006/0121005 (2006-06-01), Berenson et al.
patent: WO95/00642 (1995-01-01), None
patent: WO95/03408 (1995-02-01), None
patent: WO 95/33823 (1995-12-01), None
patent: WO99/36093 (1999-07-01), None
patent: WO00/25813 (2000-05-01), None
patent: WO 03/006632 (2003-01-01), None
patent: WO03/057171 (2003-07-01), None
patent: WO03/065977 (2003-08-01), None
Zhu et al. The Journal of Immunology, 2001 167:2671-2676.
Zamai et al. Eur. J. Histochem. 1994 38 suppl I:53-60.
Yotnda et al. J. Clin. Invest. 1998 101;10:2290-2296.
ATCC Cell Lines and Hybridomas 1994 8th Edition, p. 129.
Britten et al. Journal of Immunological Methods. 2002, 259:95-110.
Fanger et al. The Journal of Immunology, 1996, 157:541-548.
San Jose et al. Eur. J. Immunol. 1998. 28:12-21.
Thomas, A.K. et al., “A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes,”Clinical Immunology 105(3): 259-272, Dec. 2002.
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science 274:94-96, Oct. 1996.
Brodie et al., “In Vivo Migration and Function of Transferred HIV-1-Specific Cytotoxic T Cells,”Nature Medicine 5(1):34-41, Jan. 1999.
Chapoval et al., “B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-γProduction,”Nature Immunology 2(3):269-274, Mar. 2001.
Dudley et al., “Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma,”J. of Immunotherapy 24(4):363-373, Jul./Aug. 2001.
Dunbar et al., “Direct Isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood,”Current Biology 8(7):413-416, Mar. 1998.
Curtsinger et al., “CD8+Memory T Cells (CD44high, Ly-6C+) Are More Sensitive than Naïve Cells (CD44low, Ly-6C−) to TCR/CD8 Signaling in Response to Antigen,”J. of Immunol. 160:3236-3243, 1998.
Dong et al., “B7-H1, A Third Member of the B7 Family, Co-Stimulates T-Cell Proliferation and Interleukin-10 Secretion,”Nature Medicine 5(12):1365-1369, Dec. 1999.
Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,”J. of Exp. Medicine 192:1027-1034, 2000.
Guinn et al., “4-1BBL Cooperates with B7-1 and B7-2 in Converting a B Cell lymphoma Cell Line into a Long-Lasting Antitumor Vaccine,”J. of Immunol. 162:5003-5010, 1999.
Heslop et al., “Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes,”Nature Medicine 2(5):551-555, May 1996.
Hurtado et al., “Potential Role of 4-1BB in T Cell Activation,”J. of Immunol. 155:3360-3367, 1995.
Hurtado et al., “Signals Through 4-1BB are Costimulatory to Previously Activated Splenic T Cells and Inhibit Activation-Induced Cell Death,”J. of Immunol. 158:2600-2609, 1997.
Iezzi et al., “The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells,”Immunity 89(1):89-95, Jan. 1998.
Kato et al., “Gene Transfer of CD4O-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells,”J. of Clinical Investigation 101(5):1133-1141, Mar. 1998.
Latchman et al., “PD-L2 is a Second Ligand for PD-1 and Inhibits T Cell Activation,”Nature Immunology 2(3):261-268, Mar. 2001.
Levine et al., “Effects of CD28 Costimulation on Long-Tern Proliferation of CD4+T Cells in the Absence of Exogenous Feeder Cells,”J. of Immunol. 159(12):5921-5930, 1997.
Li et al., “IL-15 and IL-2: A Matter of Life and Death for T Cells in Vivo,”Nature Medicine 7(1):114-118, Jan. 2001.
Liebowitz et al., “Costimulatory Approaches to Adoptive Immunotherapy,”Curr. Opin. in Onc. 10(6):533-541, Nov. 1998.
Maus et al., “Ex Vivo Expansion of Polyclonal and Antigen-Specific Cytotoxic T Lymphocytes by Artificial APCs Expressing Ligands for the T-Cell Receptor, CD28 and 4-1BB,”Nature Biotech. 20:143-148, Feb. 2002.
Melero et al., “Amplification of Tumor Immunity by Gene Transfer of the Co-Stimulatory 4-1BB Ligand: Synergy with the CD28 Co-Stimulatory Pathway,”Eur. J. of Immunol. 28(3):1116-1121, Mar. 1998.
Melero et al, Monoclonal Antibodies Against the 4-1BB T-Cell Activation Molecule Eradicate Established Tumors,Nature Medicine 3(6):682-685, Jun. 1997.
Melief et al., “T-Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes,”Immunological Reviews 146:167-177, 1995.
Ranheim et al., “Activated T Cells Induce Expressions of B7/BB1 on Normal or Leukemic B Cells Through a CD40-Dependent Signal,”J. of Exp. Med. 177(4):925-935, Apr. 1993.
Riddell et al., “The Use of Anti-CD3 and Anti-CD28 Monoclonal Antibodies to Clone and Expand Human Antigen-Specific T Cells,”J. of Immunological Methods 128(2)189-201, 1990.
Riddell et al., “The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology Oct. 7, 1991,”Human Gene Therapy 3(3):319-338, Jun. 1992.
Riddell et al., “Principles for Adoptive T Cell Therapy of Human Viral Diseases,”Annu. Rev. Immunol. 13:545-586, 1995.
Riddell et al., “Restoration of Vital Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones,”Science 257:238-241, Jul. 1992.
Rooney et al., “Infusion of Cytotoxic T Cells for the Prevention of and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients,”Blood 92(5):1549-1555, Sep. 1998.
Rosenberg et al., “Gene Transfer into Humans—Immunotherapy of Patients with Advanced Melanoma, using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction,”N. Engl. J of Med. 323(9)570-578, Aug. 1990.
Rosenberg et al., “Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma,”N. Eng. J. of Med. 319(25):1676-1680, Dec. 1988.
Sagerström et al., “Activation and Differentiation Requirements of Primary T Cells in Vitro,”Proc. Natl. Acad. Sci. 90:8987-

Affiliated with

Also associated with

Rating

Activation and expansion of T-cells using an engineered... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation and expansion of T-cells using an engineered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation and expansion of T-cells using an engineered... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4093002